Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
Tanawin NopsoponNora A BarrettWanda PhipatanakulTanya M LaidlawScott T WeissAyobami T AkenroyePublished in: Allergy (2024)
and FVC with distinct post-initiation trajectories.